title: Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies.
abstract: Recently, the use of platinum-containing antineoplastic agents for extended periods has increased. In this study, we determined the relationship between the hypersensitivity reactions to cisplatin or carboplatin and the frequency of administration among patients with thoracic malignancies. The study included 255 patients with thoracic malignancies who were treated with chemotherapy containing cisplatin or carboplatin in our institution between April 2007 and October 2008. A total of 89 patients received a median of 3 courses of cisplatin and 140 patients a median of 4 courses of carboplatin. A median of 6 courses of cisplatin plus carboplatin was administered to a further 26 patients. The total incidence of hypersensitivity reactions was 1.96%. Patients who were treated with <6 courses of platinum-containing antineoplastic agent did not experience any hypersensitivity reaction, but one patient, who was administered with 6 courses of platinum-containing antineoplastic agent experienced a hypersensitivity reaction (0.44%), as did four patients who were administered ≥7 courses (13.8%). Univariate and multivariate analyses indicated that the number of courses of platinum-containing antineoplastic agents was significantly correlated to the incidence of hypersensitivity reactions to these agents.
authors.affiliation: Department of Thoracic Malignancy, Osaka Prefectural Hospital Organization Osaka Prefectural Medical Center for Respiratory and Allergic Diseases, Habikino 3-7-1 Habikino city, Osaka 583-8588, Japan. moto19781205@yahoo.co.jp
authors.forename: Motohiro
authors.initials: M
authors.lastname: Tamiya
authors.forename: Hanako
authors.initials: H
authors.lastname: Kuhara
authors.forename: Tomonori
authors.initials: T
authors.lastname: Hirashima
authors.forename: Yoko
authors.initials: Y
authors.lastname: Kondo
authors.forename: Masumi
authors.initials: M
authors.lastname: Santo
authors.forename: Naoko
authors.initials: N
authors.lastname: Morishita
authors.forename: Hidekazu
authors.initials: H
authors.lastname: Suzuki
authors.forename: Shinji
authors.initials: S
authors.lastname: Sasada
authors.forename: Norio
authors.initials: N
authors.lastname: Okamoto
authors.forename: Masashi
authors.initials: M
authors.lastname: Kobayashi
authors.forename: Ichiro
authors.initials: I
authors.lastname: Kawase
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016190:Carboplatin / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use*; D004342:Drug Hypersensitivity / Q000209:etiology; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000737:chemistry; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D013899:Thoracic Neoplasms / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000970:Antineoplastic Agents; D007073:Immunoglobulin E; D016190:Carboplatin; D002945:Cisplatin